Clinical Trials Logo

Clinical Trial Summary

This is an intermediate-size patient population expanded access protocol for the use of intravenous (IV) difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.


Clinical Trial Description

Visits during the expanded access program will consist of a Baseline Visit to confirm eligibility and an End of Treatment visit. Patients will receive IV difelikefalin at a dose of 0.5 mcg/kg after each dialysis session, generally 3 times per week. The End of Treatment visit will be defined as the first dialysis visit following the last dose of IV difelikefalin under the intermediate-size patient population expanded access protocol. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05031546
Study type Expanded Access
Source Cara Therapeutics, Inc.
Contact Frédérique Menzaghi, PhD
Phone 203-406-3700
Email [email protected]
Status Available
Phase

See also
  Status Clinical Trial Phase
Recruiting NCT04728984 - A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet Phase 3
Completed NCT02143973 - Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Terminated NCT01660243 - Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis Phase 2
Recruiting NCT04470154 - A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis Phase 2
Completed NCT03002233 - TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus Phase 1
Completed NCT03998163 - CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 3
Recruiting NCT04393675 - Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients Phase 1/Phase 2
Completed NCT03576235 - Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients N/A
Completed NCT02858726 - Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 2/Phase 3
Completed NCT02143648 - Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Completed NCT00494975 - The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease N/A
Completed NCT03758079 - Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus Phase 4
Completed NCT02229929 - Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus Phase 2
Recruiting NCT04639674 - AST-120 in Hemodialysis Patients With Uremic Pruritus N/A
Completed NCT03636269 - CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 3
Active, not recruiting NCT04711603 - A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. Phase 3
Completed NCT02696499 - Treatment of Uremic Pruritus With PA101B Phase 2
Completed NCT03422653 - A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1) Phase 3
Completed NCT03802617 - A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. Phase 2
Not yet recruiting NCT00793156 - A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch) Phase 3